Heidelberg Pharma (HPHA) Q1 2025 earnings summary

Executive summary

• Q1 clinical progress: HDP-101 cohort 7 at 112.5 µg/kg was safe and well tolerated; cohort 8 is planned at 140 µg/kg, and clinical testing of HDP-102 has started.

• A March amendment with HealthCare Royalty delivered USD 20 million upfront; with the expected USD 70 million payment upon TLX250-CDx FDA approval, current planning extends funding into 2027.

Financial highlights

• Q1 sales revenue was EUR 1.270 million versus EUR 1.267 million YoY; other income was EUR 1.603 million versus EUR 0.592 million, primarily from a milestone tied to the 2023 sale of a minority interest.

• Operating expenses rose to EUR 8.991 million from EUR 6.566 million; operating result was a loss of EUR 6.118 million versus EUR 4.707 million.

• Net loss was EUR 5.938 million versus EUR 4.494 million; basic EPS was EUR -0.13 versus EUR -0.10.

Outlook and guidance

• FY2025 sales revenue and other income are forecast at EUR 9.0–11.0 million; operating expenses at EUR 40.0–45.0 million and operating loss at EUR 30.0–35.0 million.

• Expected cash inflow of EUR 50.0–55.0 million includes a further HCRx payment; current budget, including the expected USD 70 million approval payment less transaction costs, funds operations into 2027.

• Cash funds for business operations are expected to improve significantly versus 2024 if income and expenses develop as anticipated.